Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 19, 2016

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Breast CancerEarly StageTriple Negative Breast Cancer
Interventions
DRUG

Enzalutamide

BEHAVIORAL

assessment

Trial Locations (12)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11203

Kings County Hopsital Center, Brooklyn

11235

Coney Island Hospital, Brooklyn

11432

Queens Hospital Center, Jamaica

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

18103

Lehigh Valley Health Network, Allentown

06102

Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

Unknown

Woodhull Hospital, Brooklyn

Sponsors
All Listed Sponsors
collaborator

Medivation, Inc.

INDUSTRY

collaborator

Astellas Pharma Inc

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER